ERBB2 and hepatocellular carcinoma: Patients with tumors that express PD-L1 and cannot receive platinum-based chemotherapy or do not respond to this therapy.In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of Atezolizumab only for the urothelial carcinoma. Rest of indications remain unaffected: Non-small cell lung cancer; Breast cancer (PD-L1 expressed, HR negative, HER2 negative); Small cell lung cancer; Hepatocellular carcinoma.